TRDA250117C17500
- 2.45
- -0.84-25.53%
Entrada Therapeutics Newsroom
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PepGen Stock Craters 35% on FDA Clinical Hold
Are Strong Financial Prospects The Force That Is Driving The Momentum In Entrada Therapeutics, Inc.'s NASDAQ:TRDA) Stock?
Roth MKM Starts 'Overlooked' Entrada Therapeutics With Buy Rating
Roth Initiates Entrada Therapeutics at Buy
H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $29
Entrada Therapeutics Price Target Announced at $29.00/Share by Roth MKM
Entrada Therapeutics Insider Sold Shares Worth $339,281, According to a Recent SEC Filing
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $28
Oppenheimer Adjusts Entrada Therapeutics Price Target to $28 From $25, Maintains Outperform Rating
Entrada Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Entrada Therapeutics Analyst Ratings
H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $20
Entrada Therapeutics: Strong Buy Recommendation Backed by Promising Clinical Progress and Robust Financial Health
Express News | Entrada Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $20 From $18
TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating
TD Cowen Sticks to Its Buy Rating for Entrada Therapeutics Inc (TRDA)
Entrada Therapeutics GAAP EPS of -$0.35 Beats by $0.44, Revenue of $19.57M Beats by $7.69M
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates